High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results

Bone Marrow Transplantation

Volumn 18, Issue SUPPL. 1, 1996, Pages

  Cagnoni, Pablo J ^a   Shpall, Elizabeth J ^a   Bearman, Scott I ^a   Ross, Maureen ^a   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG FATALITY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LUNG TOXICITY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RECURRENT CANCER; SENSORY NEUROPATHY; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BREAST NEOPLASMS; CLINICAL TRIALS; COLORADO; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM CIRCULATING CELLS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029958594     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. National Institutes of Health Consensus Development Conference on Early-Stage Breast Cancer, June 18-21, 1990, Bethesda, MD.
2. Carter CL, Allen C, Henson DC. Relation of tumor size, lynch node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989.
3. Nemoto T, Vana J, Bedwani RN, et al. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45:2917, 1980.
4. Fisher B, Kent Osborne C, Margolese R, Bloomer W. Neoplasms of the breast. In: Cancer Medicine, edited by Holland JF, Frei E III, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. Philadelphia, Lea & Febiger, 1993, pp1706-1774.
5. Schabel FM. Animal models as predictive systems. In: Cancer chemotherapy-fundamental concepts and recent advances. Chicago: Year Book Medical Publishers, pp323-355, 1975.
6. Steel GG. Growth and survival of tumor stem cells. In: Growth kinetics of tumors. Oxford: Clarendon Press, pp244-267, 1977.
7. Teicher B, Holden SA, Cucchi CA, et al. Combination of N,N′N″-triethylenethiophosphamide and cyclophosphamide in vitro and in vivo. Cancer Res, 48:94-100, 1988.
8. Frei E III, Cucchi C, Rosowsky A, et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 82:2158-2162, 1985.
9. Frei E III, Teicher B, Cucchi C, et al. Resistance to alkylating agents: basic studies and therapeutic implications. In: Mechanisms of drug resistance in neoplastic cells, edited by Wooley P III and Tew K, New York, Academic Press, 1988, pp 69-87.
10. Herzig RH. The role of bone marrow transplantation in the treatment of solid tumors. Sem Oncol 19:7-12, 1992.
11. Hryniuk W, Bush H. The importance of Dose Intensity in Chemotherapy of Metastatic Breast Cancer. J Clin Oncol 2:1281-1288, 1984.
12. Tannock IF, Boyd NF, Deboer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6.1377-1387, 1988.
13. Jones RB, Shpall EJ, Ross M, et al: AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for the treatment of breast cancer. Current results. Proc Am Soc Clin Oncol 7:121, 1990 (abstr 30).
14. Dunphy FR, Spitzer G: Use of very high dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst 84:128-129, 1992.
15. Grad G, Lane N, Zimmerman T, et al: High-Dose chemotherapy and autologous stem cell support in breast cancer: The University of Chicago experience. Proc Am Soc Clin Oncol 13:73, 1994 (abstr 94).
16. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10:102-110, 1992.
17. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995.
18. Peters WP, Ross M, Vredenburgh JJ, et al. High-Dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk breast cancer. J Clin Oncol 11:1132-1143, 1993.
19. Bearman SI, Overmoyer BA, Bolwell BG, et al. High-dose chemotherapy with autologous peripheral blood progenitor cell for primary breast cancer in patients with 4-9 involved axillary lymph nodes: a feasibility study. Proc Am Soc Clin Oncol 1996 (in press).
20. Bearman SI (personal communication).
21. Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12:28-36.
22. Cagnoni PJ, Jones RB, Franklin W, et al. Use of CD34-positive autologous hematopoietic progenitors to support patients with breast cancer after high-dose chemotherapy. Blood 1995; 86:386a.
23. Stemmer SM, Cagnoni PJ, Shpall EJ, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor cell support. A phase I trial. J Clin Oncol (in press).
24. Cagnoni PJ, Shpall EJ, Bearman SI, et al. Paclitaxel containing high-dose chemotherapy. The University of Colorado Experience. Sem Oncol (in press).
25. 90Y Mx-DTPA-BrE-3 and autologous hematopoietic stem cell support for the treatment of advanced breast cancer: A phase I trial. Cancer Res 55 (23):5921S-24S, 1995.